Search

FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD

Nintedanib Study: Systemic Sclerosis & Lung Fibrosis | Boehringer Ingelheim US

Boehringer Ingelheim today announced that the first patient was enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in SystemicSClerosIS) study.

The Central Role of Primary Care Physicians and Endocrinologists in Treating C-R-M Conditions | Boehringer Ingelheim US

The Central Role of Primary Care Physicians and Endocrinologists in Treating C-R-M Conditions

Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases

New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism

Jardiance® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes regardless of the type of cardiovascular disease at baseline

Clinical trials deliver medical breakthroughs – but how do they happen?

Clinical trials deliver medical breakthroughs – but how do they happen? Prof. Dr Martina Brueckmann talks about her role getting new drugs to trial.

Reducing Stress in Horses – With Music

Click here to read more on the release of the Boehringer Ingelheim specially composed music track, designed to keep horses safe and "sound".

Our Partners: ViraTherapeutics

Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF

Empowering Employees to be Their Own Superheroes

Bringing focus to unmet needs in biliary tract and pancreatic cancer with the Brightline-2 Trial

Brightline-2 clinical trial is studying our investigational MDM2-p53 antagonist for people with advanced cancer in the biliary tract or pancreatic cancer.

OFEV® (nintedanib) Now Available in the United States

Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders

Baseball Legend Bernie Williams Calls on the Public to Join Queen Latifah, The Bacon Brothers, Paul Shaffer, as Judges of the Breathless® Ballad Challenge

Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic

The power of patient advocacy in cancer care

Patients and advocacy organizations agree that patient empowerment is key to quality cancer care

Boehringer Ingelheim and the Lieber Institute for Brain Development To Collaborate to Develop Centrally Acting COMT Inhibitors For the Treatment of Neuropsychiatric Disorders

FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD

Animal Health Innovation

Asthmatic Horse's First Inhaled Therapy | Boehringer Ingelheim US

Click here to read about Boehringer Ingelheim launching the first inhaled therapy for horses suffering with severe asthma in the United States.

Boehringer Ingelheim’s Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation

Foot & Mouth Disease: Know the Facts | Boehringer Ingelheim US

Click here to read more on how the US is planning to create a vaccine bank to guard against and prevent foot-and-mouth disease in livestock across the USA.

SEMINTRA® (Telmisartan Oral Solution) | Boehringer Ingelheim US

Introducing SEMINTRA® (telmisartan oral solution) —The first FDA-approved liquid solution for the control of systemic feline hypertension.

Are combination therapies the answer to battling KRAS cancers?

Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers